NCT01344798已完成1 期
Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Genethon
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Number of patients with adverse events or general or local signs as a measure of clinical safety
研究概览
简要总结
The purpose of this trial is to study the evaluation of clinical safety and feasibility of gene therapy in patients with limb girdle muscular dystrophy type 2C (gamma-sarcoglycanopathy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of LGMD 2C including:
- •Molecular analysis proving del525T mutation on γ-sarcoglycan gene (chromosome 13) at homozygous state
- •Muscle biopsy with immunohistochemical and/or Western blot analyses showing marked decrease or absence of γ-sarcoglycan staining in muscle, as well as a fibrosis assessment should be available. If not, an initial muscular biopsy may be performed during the pre-enrollment period
- •Lower age limit of 15 years
- •Males and females may be equally enrolled
- •Adequate carpi radialis muscle bulk for muscle biopsy as assessed by examination. Subjects should be able to communicate with the investigation staff. They should be able to understand, to comply with and to perform all needed evaluations during the trial period, including muscle strength tests. Forearm muscle strength should be of at least 3+ as assessed through the British Medical Research Council (MRC) Manual Muscle Testing (MMT) scale.
- •Subjects should also have already lost ambulation
- •Subjects should be able and willing to return for follow up
- •Subjects should be able and willing to give signed informed consent. For minor subjects, a signed informed consent will be given by legally authorized representative
- •Eligible subjects belonging to a multiplex family should not be enrolled in the same cohort.
排除标准
- •Severity of disease and presence of ill-prognosis complications:
- •Severe respiratory dysfunction such as subjects with tracheostomy or forced vital capacity (FVC) < 1000 ml and/or < 30%;
- •Uncompensated heart failure;
- •An ejection fraction (EF) < 30% as measured on either echocardiography or scintigraphy;
- •Severe rhythm disturbances and/or high degree conduction defect in the absence of a pacemaker insertion.
- •Underlying conditions, diseases or active viral infections likely to increase risk of complications or to interfere with the investigational treatment:
- •contraindications for injections and muscle biopsies
- •Platelet count < 100,000 / mm3
- •Total bilirubin > 10 mg/l (> 17 µmol/l)
- •Serum creatinin > 110 µmol/l
- •Lymphocytes CD4+ < 250/mm3 (< 15%)
- •History of diabetes mellitus
- •Current infectious diseases, including known positive HIV serology, hepatitis B and C
- •Abnormal profile on protein immunoelectrophoresis
- •Immunizations of any kind within the past month
- •receipt of another investigational agent within 4 weeks of study enrollment
- •History of or current steroid medication for indications other than muscular dystrophy, chemotherapy, radiotherapy or other immunosuppressive therapy. Steroid medication, if any, should be discontinued at least 3 months before entering the protocol and not received during the study
- •Pregnant or lactating women. Females or males of childbearing age must be willing to employ adequate contraception, that is to use condoms during the 3 months following the administration of the product
- •Pre-injection neutralizing anti-AAV1 antibodies titer (on pre-enrollment / D-30 visit) superior or equal to 1/800.
结局指标
主要结局
Number of patients with adverse events or general or local signs as a measure of clinical safety
时间窗: 6 months
Standard general and local clinical examination as well as vital signs assessement, including pain, local inflammation, stiffness and fatigability.
次要结局
- Number of patients with modified biological values (blood count, standard biochemistry, viral serology)(6 months)
- number of patients with changed or increased humoral immunity to AAV(6 months)
- Number of patients with changed/increased humoral immunity to transgene(6 months)
- Number of patients with changed/increased cellular immunity to AAV(6 months)
- Number of patients with changed/increased cellular immunity to transgene(6 months)
- number of patients with positively stained muscular fibers to gamma-sarcoglycan protein(30 days)
- Number of patients with modified/decreased muscular force(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Studying the feasibility and safety of gene therapy to treat limb girdle muscular dystrophy (LGMD) type 2Cimb girdle muscular dystrophy (LGMD), type 2C (gamma-sarcoglycanopathy)Musculoskeletal DiseasesLimb girdle muscular dystrophy (LGMD), type 2C (gamma-sarcoglycanopathy)ISRCTN22225367Genethon (France)9
招募中
1 期
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 GeneRetinitis PigmentosaNCT06291935ViGeneron GmbH6
已完成
1 期
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaAcute Intermittent PorphyriaNCT02082860Digna Biotech S.L.8
已完成
1 期
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML PatientsMyelodysplastic Syndromes (MDS)Acute Myeloid Leukaemia (AML)NCT02550535Cell Medica Ltd3
终止
1 期
A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant OsteopetrosisInfantile Malignant OsteopetrosisNCT04525352Rocket Pharmaceuticals Inc.1